All In Biotech

Drug Trial Radar · NCT06996951

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

Sinonasal Therapies and Histologic Correlations for Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jul 2, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Rhinologic Society
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain standard Sino nasal therapies such as high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibiotics. They are also going to study the fluid inside the nose to see if there are changes when stopping these therapies. Right now, they are not sure if it is suggested to stop these treatments when patients begin highly effective modulator therapy (HEMT)

Conditions

  • Cystic Fibrosis (CF)
  • Chronic Rhinosinusitis (CRS)

Interventions

  • STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROIDOther

    PATIENT WILL STOP USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

  • CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROIDDrug

    PATIENT WILL CONTINUE USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Lund Kennedy ScoreTime frame: Baseline, 12 weeks
  2. Change in Pulmonary Function TestingTime frame: Baseline, 12 weeks
  3. Change in Body Mass Index (BMI)Time frame: Baseline, 12 weeks
  4. Change in Health Care UtilizationTime frame: Baseline, 12 weeks
  5. Change in Sinonasal Outcome Test 22 Questionnaire (SNOT-22) ScoreTime frame: Baseline, 12 weeks
  6. Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) ScoreTime frame: Baseline, 12 weeks
  7. Change in Patient Health Questionnaire-9 (PHQ-9) ScoreTime frame: Baseline, 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indiana University Health

    Indianapolis, Indiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.